NMNikola Mitrev

Nikola Mitrev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nikola Mitrev has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exploring the Perceptions and Practices of Exclusive Enteral Nutrition Among Adult Patients With Inflammatory Bowel Disease, Gastroenterologists and Dietitians in Australia

    by Brook Maguire, Nikola Mitrev, Brandon Baraty, Michael Au, Kyle Sorensen, Viraj Kariyawasam

    Background: Exclusive enteral nutrition (EEN) is potentially underutilised among adult inflammatory bowel disease (IBD) patients. We explore current practices and perceptions of EEN among patients, dietitians and gastroenterologists. Methods: Electronic surveys were developed for patients, dietitians and gastroenterologists in Australia. Surveys were distributed during national conferences and via social media platforms. Results: Surveys were taken by 67 patients, 135 dietitians and 100 gastroenterologists. Although 99% of the gastroenterologists were aware of EEN, only 39% routinely used EEN. Patient adherence was the most common reason for not utilising EEN, followed by limited dietitian support, limited clinician experience and cost. Of the surveyed patients, 64% had Crohn's Disease and 36% had ulcerative colitis. EEN had previously been tried by 21% patients of which 92% reported completing the entire EEN regimen. Majority (75%) were open to recommencing EEN in the event of future flares with/without additional medication. Among patients never treated with EEN, 72% preferred EEN with/without medication over medication alone. Most patients (95%) preferred remote dietitian consultations either exclusively (59%) or along with in‐person sessions (36%). Many dietitians (39%) did not feel they had adequate knowledge or experience to manage patients with IBD on EEN. Conclusion: Although majority of patients with IBD favour trying EEN, most gastroenterologists do not routinely use EEN. Gastroenterologists' perception of poor adherence as a major barrier may be incorrect. Majority of EEN experienced patients report completed the regimen and a willingness to re‐try it. A strong patient preference for remote consultations can improve access to experienced dietitians.

  • Open Access

    Determining efficacy of dynamic multimedia bowel preparation instructions versus standard instructions on adenoma detection and patient reported measures (DIGICLEAN trial): a study protocol for a multicentre, colonoscopist-blinded, randomised controlled trial

    by Michael Au, Patrick Low, Michael Rennie, Marriam Mohseni, Yang Song, Narae Kim, Brandon Baraty, Nikola Mitrev, Emily He, Vincent Ho, et al.

    Introduction Colonoscopy plays important roles in bowel cancer screening and treatment. Poor bowel preparation occurs in 20–25% of colonoscopies. This negatively impacts adenoma and sessile serrated lesion detection rates, procedural time, requirement for repeat colonoscopies, healthcare costs and likelihood of patient withdrawal from screening programmes. It is unclear whether a combination of multimedia modalities can improve bowel preparation quality, adenoma detection rates and patient-reported measures in those undergoing colonoscopy assessment. Methods The DIGICLEAN trial is a prospective, parallel, multicentre, colonoscopist-blinded, randomised controlled trial. The trial will enrol 1294 participants aged 45 years and older who are indicated for a colonoscopy as an outpatient with a positive faecal occult blood test, iron deficiency anaemia or rectal bleeding. Participants will be randomised into the interventional arm, where bowel preparation instructions are delivered via a web-based application which uses scheduled short messaging service, regular patient survey assessment, email and videos; or the control arm, where routine standard written, verbal or emailed instructions are administered. The web-based application will assess patient-reported bloating, constipation and dietary adherence leading up to the colonoscopy. Depending on patient responses, additional aperients may be encouraged digitally in the interventional arm with same instructions made available in written format for the control arm. Patient-reported measures will be collected in both arms the day after the procedure using the validated Newcastle ENDOPREM questionnaire. In some sites, participants will undergo digital pre-anaesthetic screening as well. The co-primary endpoints are the adenoma detection rates and patient-reported measures taken after the colonoscopy. Ethics and dissemination Ethics approval for this study was obtained from the Western Sydney Local Health District Human Research Ethics Committee (2022/ETH00059). Findings will be reported at national and international gastroenterology meetings and published in peer-reviewed journals. Trial registration number ACTRN12622000747729.


  • Adolescents and young adults communicating with gastroenterologists: variation in inflammatory bowel disease clinical communication

    by Neda Karimi, Annabelle Lukin, Alison R. Moore, Joseph L. Pipicella, Ria Kanazaki, Astrid-Jane Williams, Watson Ng, Viraj Kariyawasam, Nikola Mitrev, Keval Pandya, et al.

    Objectives: This study explored the variation in emerging adults’ communication with gastroenterologists around the management of inflammatory bowel disease (IBD). Methods: Nineteen emerging adults with IBD aged 18–25 and seven gastroenterologists participated in the study. Outpatient specialist consultations of consenting participants were audio-recorded and transcribed. Transcribed consultations were analysed in terms of the linguistic structure of the consultations and the gastroenterologist-patient role relationship. Results: Variations in the emerging adults’ communication with their gastroenterologists stem partly from variation in their ability, opportunity, or need to contribute to the different phases of the consultation and partly from variations in the gastroenterologists’ style of communication. Gastroenterologists differed in the construction of their role relationship with the patient, resulting in variations in employing empowering strategies including eliciting, exploring, and clarifying the patient’s concerns, sharing clinical reasoning, and validating the patient experience. Variations were also observed in the length of appointments and the gastroenterologists’ assessment and addressing of adherence issues. Techniques used by the gastroenterologist varied (1) from simply confirming adherence, to a comprehensive assessment of the patient’s understanding of their management plan and their feedback, and (2) from use of persuasion to values calibration. Conclusions: Evidence-based consumer interventions and communication guidelines for clinicians are needed to address the identified variations in providing care to emerging adults living with chronic conditions.


  • Review article: consensus statements on therapeutic drug monitoring of anti‐tumour necrosis factor therapy in inflammatory bowel diseases

    by N. Mitrev, N. Vande Casteele, C. H. Seow, J. M. Andrews, S. J. Connor, G. T. Moore, M. Barclay, J. Begun, R. Bryant, W. Chan, et al.

    Summary: Background: Therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD) patients receiving anti‐tumour necrosis factor (TNF) agents can help optimise outcomes. Consensus statements based on current evidence will help the development of treatment guidelines.Aim: To develop evidence‐based consensus statements for TDM‐guided anti‐TNF therapy in IBD.Methods: A committee of 25 Australian and international experts was assembled. The initial draft statements were produced following a systematic literature search. A modified Delphi technique was used with 3 iterations. Statements were modified according to anonymous voting and feedback at each iteration. Statements with 80% agreement without or with minor reservation were accepted.Results: 22/24 statements met criteria for consensus. For anti‐TNF agents, TDM should be performed upon treatment failure, following successful induction, when contemplating a drug holiday and periodically in clinical remission only when results would change management. To achieve clinical remission in luminal IBD, infliximab and adalimumab trough concentrations in the range of 3‐8 and 5‐12 μg/mL, respectively, were deemed appropriate. The range may differ for different disease phenotypes or treatment endpoints—such as fistulising disease or to achieve mucosal healing. In treatment failure, TDM may identify mechanisms to guide subsequent decision‐making. In stable clinical response, TDM‐guided dosing may avoid future relapse. Data indicate drug‐tolerant anti‐drug antibody assays do not offer an advantage over drug‐sensitive assays. Further data are required prior to recommending TDM for non‐anti‐TNF biological agents.Conclusion: Consensus statements support the role of TDM in optimising anti‐TNF agents to treat IBD, especially in situations of treatment failure.


  • Open Access

    Editorial: infliximab trough cut‐off for perianal Crohn's disease – another piece of the therapeutic drug monitoring‐guided infliximab dosing puzzle

    by N. Mitrev, V. Kariyawasam, R. W. Leong

    Linked ContentThis article is linked to Yarur et al paper. To view this article visit https://doi.org/10.1111/apt.13970.